<?xml version="1.0" encoding="UTF-8"?>
<p id="Par20">Current medical recommendations are directed towards resolving symptoms and not the actual infection; however, ZIKV treatments and vaccines are in development. In 2016, WHO enlist all publicly affirmed commercial, government and academic-led projects focused at ZIKV interventions, together with vaccines [
 <xref ref-type="bibr" rid="CR69">69</xref>]. The list encompasses numerous approaches, comprising vaccines via purified inactivated virus, Virus-like particles (VLP), protein subunits, DNA and live recombinant attenuated viruses. Since April 2019, no vaccines have been permitted for clinical usage, though utmost were in the clinical stages of development [
 <xref ref-type="bibr" rid="CR70">70</xref>, 
 <xref ref-type="bibr" rid="CR71">71</xref>].
</p>
